Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Q1 2026
Tonix Pharmaceuticals Holding (TNXP) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 11, 2026
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $6.9M for the first quarter 2026 (Q1 2026), +183% from a year earlier and +28% from the quarter before. Operating margin was -603.9%, net loss $40.2M (584.4% of revenue).
Tonix Pharmaceuticals Holding, Q1 2026: revenue $6.9M (+183% year over year), operating margin -603.9%, net loss $40.2M, operating cash flow −$42.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.9M | +28% | +183% |
| Operating profit | −$41.5M | — | — |
| Net earnings | −$40.2M | — | — |
| Operating cash flow | −$42.3M | — | — |
What changed
Revenue was $6.9M in Q1 2026, up 183% year over year and up 28% from the previous quarter. Tonmya was the largest line at 54% of revenue. Zembrace Symtouch added $904K year over year (up 45%), 20% of the total change. Tosymra declined 46%.
Operating costs exceeded revenue by $41.5M, an operating margin of -603.9%. Total costs grew 162% against revenue growth of 183%. The fastest-growing cost line was SG&A (+183%). The quarter ended with a net loss of $40.2M, narrower than the previous quarter's $46.9M loss.
Operating cash flow was −$42.3M. Non-cash charges added back $555K of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $4.6M. Capital expenditures of $1.7M exceeded it, leaving free cash flow of −$44.0M.
Questions
What was Tonix Pharmaceuticals Holding's revenue in the first quarter 2026?
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $6.9M for the first quarter 2026 (Q1 2026), +183% from a year earlier and +28% from the quarter before.
Was Tonix Pharmaceuticals Holding profitable in the first quarter 2026?
Operating loss was $41.5M (-603.9% of revenue) and net loss $40.2M.